Services Provided

• Strategic and tactical guidance on the design, development, and manufacture of immediate-release and controlled-release medicines for human use
• Formulation strategies for low solubility drugs to enhance exposure and bioavailability
• Expert advice on the selection, use, and testing of pharmaceutical materials
• Problem solving related to dosage form design and development
• Intellectual property strategy development and expert witness services
• Diligence investigations for business development
• Technical training for students, scientists, and managers in the health care sector
• Support for regulatory interactions (queries, face-to-face meetings, etc)

Our Clients

• Large and mid-size multinational pharmaceutical companies
• Start-ups and virtual businesses
• Venture capital investors
• Universities and government agencies
• Attorneys, plaintiffs, and defendants
• Regulatory agencies and standard setting organizations
• Not-for-profit organizations and charitable foundations

Who We Are

Sheri Shamblin, PhD has been a scientific leader in oral drug product development for over twenty-five years. Her expertise includes developing end-to-end drug product development strategies, including early clinical formulation design and progression of Phase III formulations to commercial medicines. Sheri is a recognized expert in the development of immediate release and oral controlled release formulations, including the use of enabling strategies to increase API solubility and in-vivo exposure. Throughout her industrial career, she has worked collaboratively with discovery and commercial asset teams to leverage drug delivery technologies (e.g., oral CR dosage forms, amorphous solid dispersions and multiparticulates) to achieve specific clinical objectives and bring new medicines to the market.

Bruno Hancock, PhD is a globally recognized authority on pharmaceutical materials and formulation design. From 2013 to 2024 Bruno was the Head of Materials Science at Pfizer Inc. and led a group of over fifty scientists to design, select and characterize Pfizer’s new drug candidates. He was involved in the commercialization of multiple blockbuster medicines (including Vioxx®, Xeljanz®, and Paxlovid®) and the acquisition of several more (Mektovi®/Bravtovi®, Velsipity®, Xtandi®, Nurtec®). Dr. Hancock has acted as an expert advisor to the United State Pharmacopeia (USP) on the properties of pharmaceutical materials since 1995, and he currently serves as an Editor for both the Journal of Pharmaceutical Sciences and the Handbook of Pharmaceutical Excipients. In 2000, Bruno was the recipient of the Royal Pharmaceutical Society of Great Britain Science Medal for his contributions to pharmaceutical research and he was elected to Fellow status in the American Association of Pharmaceutical Scientists in 2004.

How We Work

Aleurites LLC is based on the US East Coast and our clients are from all over the world. Most of our work is conducted virtually but site visits and in-person connections are common. We welcome your questions, comments, and requests for information.

Contact Us

Why Aleurites?

Aleurites is a genus of flowering plants, first described in 1776. It is native to China, the Indian Subcontinent, Southeast Asia, Papuasia, and Queensland, and it is the State Tree of Hawaii. These large broadleaf evergreen trees have plumes of small creamy-white bell-shaped fragrant flowers, and walnutsized fruits that contain poisonous seeds. The oil has been used as a paraffin and lubricant, and as a constituent of varnish, paint, candles and soap. The most widespread species is the so-called “candlenut” or “Kukui” tree (Aleurites moluccanus), and it has been used in folk medicine to treat joint pain, fever, constipation, asthma, hepatitis, gastric ulcer, inflammation, and arthritis. The Kukui Nut Tree grows close by to where the founders of Aleurites LLC were married.

Source: Wikipedia & National Institutes of Health (NIH) webpage